Compare Abbott Laboratories (ABT) vs Monster Beverage Corp (MNST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Monster Beverage Corp — how do they compare? Abbott Laboratories trades at $95.2 (market cap $166.94B), while Monster Beverage Corp trades at $95.94 (market cap $94.79B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Abbott Laboratories pays a 2.63% dividend while Monster Beverage Corp pays none. Which is the better fit depends on your goals.
| ABT | MNST | |
|---|---|---|
Market Cap | $166.94B | $94.79B |
Sector | Health | Consumer Staples |
52-Week High | $136.62 | $97.64 |
52-Week Low | $82.57 | $58.65 |
Enterprise Value | $193.69B | $93.08B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Monster Beverage (MNST) trades at $96.92, down 0.7% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with revenue growing from $6.3B in 2022 to $8.3B in 2025 and net income reaching $1.91B. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $0.58 exceeding the $0.527 forecast. Analyst sentiment remains positive with 53% buy ratings, though valuation metrics appear elevated with a P/E of 47.04.
MNST presents growth opportunities through international expansion and product innovation, with overseas sales reaching 45% of revenue. However, the stock faces risks from premium valuation levels and competitive pressures in the energy drink market. The consensus price target of $91.67 suggests potential downside from current levels, while technical indicators show the stock trading near resistance at $98-$100.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →
